At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 74 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Non-small Cell Lung Carcinoma
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Acalabrutinib for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 74 participants across 1 site.
Detailed Summary
Pembrolizumab alone and in combination with acalabrutinib in subjects with advanced non-small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartMay 2015
First PostedMay 2015
Primary CompletionMar 2018
Study CompletionJun 2018
TodayJul 2026
First PostedMay 19, 2015
Enrollment StartMay 1, 2015
Primary CompletionMar 1, 2018
Study CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 11.1 years ago
Interventions
Pembrolizumabdrug
Acalabrutinibdrug